DRUG IMMUNOTARGETING FOR CARCINOMAS - A REALITY AT LAST

被引：7

作者：

CASAZZA, AM ^{[1
]}

TRAIL, PA ^{[1
]}

HELLSTROM, KE ^{[1
]}

机构：

[1] BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA

来源：

ANNALS OF ONCOLOGY | 1994年 / 5卷 / 08期

关键词：

IMMUNOTARGETING; MONOCLONAL ANTIBODY; DOXORUBICIN; BR96; IMMUNOCONJUGATES;

D O I：

10.1093/oxfordjournals.annonc.a058974

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：703 / 708

页数：6

共 33 条

[1]

[Anonymous], [No title captured]

[2]

APELGREN LD, 1990, CANCER RES, V50, P3540

[3]

BENJAMIN RS, 1975, CANCER CHEMOTH REP 3, V6, P191

[4]

BRASLAWSKY GR, 1990, CANCER RES, V50, P6608

[5]

BRASLAWSKY GR, 1989, 16TH P INT C CHEM IS

[6]

BRICH Z, 1992, J CONTROL RELEASE, V19, P245, DOI 10.1016/0168-3659(92)90080-B

[7] CHARACTERIZATION OF THE HUMAN-TUMOR AND NORMAL TISSUE REACTIVITY OF THE KS1/4 MONOCLONAL-ANTIBODY [J].

BUMOL, TF ;

MARDER, P ;

DEHERDT, SV ;

BOROWITZ, MJ ;

APELGREN, LD .

HYBRIDOMA, 1988, 7 (04) :407-415

[8]

BUMOL TF, 1987, TARGETED DIAGNOSIS T, P55

[9]

Carter S K, 1974, Semin Oncol, V1, P131

[10]

DILLMAN RO, 1988, CANCER RES, V48, P6097

← 1 2 3 4 →